SCOTUS: Drug Safety Is a Federal, Not State, Issue
By Mari Serebrov
Monday, June 24, 2013
When it comes to generic drugs, and possibly biosimilars in the future, federal law is the law of the land, the Supreme Court reiterated Monday, overturning a $21 million jury award based on state design-defect claims.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.